LepiDyne's Unique Biomarker Discovery Pipeline
DNA methylation occurs early in cancer development and progression. With our biomarker discovery pipeline, we can expand our application to other cancers to provide solutions for cancer management. We have developed highly sensitive biomarker detection technology that is applicable to early cancer diagnosis.
Marker Discovery
- LepiDyne's genomic and epigenomic database includes samples from more than 13,000 clinical cases.
- We have used our database to profile different cancers and blood methylation patterns and have identified liver cancer-specific methylation markers by machine learning.
- The discovered markers have been validated using data from different cohorts with varying ethnicity, sex, and etiology.
Detection Method
- Blood contains only minute amounts of cell-free DNA (cfDNA); therefore, diagnosis using cfDNA requires highly sensitive technology.
- We have used big data and clinical samples to establish a methylation detection method.
- Our accurate biomarkers, together with our highly sensitive detection methods and our application of algorithms, allow the early diagnosis of cancer.
- Our first product for early detection is MethyLiverDx, which measures the methylation levels of liver cancer-specific biomarkers.
About Our Technology
- We detect DNA methylation biomarkers in a patient's plasma.
- Compared to alpha-fetoprotein (AFP) screening, our method has a higher sensitivity, making it more suitable for cancer screening.
